Background
==========

Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related deaths of women living in the US \[[@B1]\]. Breast cancer manifests itself in the mammary epithelium; however, tumors do not progress to malignancy in isolation. The local microenvironment can enhance or suppress tumor growth and progression, as well as metastases \[[@B2]-[@B8]\]. The stroma is composed of diverse cell types including endothelial and immune cells, adipocytes, and fibroblasts. These cells secrete products, including growth factors and extracellular matrix (ECM) components, which profoundly affect cell behavior. It has been suggested that altered communication between these cells can lead to the progression or expansion of malignant growth. While numerous studies have observed the effects of synthetic or mouse-derived ECM on breast cancer cells, relatively little is known about the molecular interactions between human breast ECM and epithelial cells.

Recently, a novel *in vivo*xenograft model mimicking human ductal carcinoma *in situ*(DCIS) illustrated that the progression of normal tissue towards a neoplastic state depends on the surrounding stromal cells \[[@B9]\]. Normal myoepithelial cells inhibited the progression of DCIS to an invasive carcinoma, while the addition of fibroblasts enhanced invasion. Additionally, reports demonstrated that the mammary microenvironment can reprogram both embryonic and adult murine stem cells into mammary cells capable of expressing milk proteins and hormone receptors, substantiating the remarkable control the environment has on cell behavior \[[@B10],[@B11]\].

African-American (AA) women have a lower overall incidence of breast cancer compared to Caucasian-American (CAU) women but a significantly higher incidence rate before the age of 40, and a higher mortality rate at any age \[[@B1]\]. Breast carcinomas in premenopausal AA patients are more often triple negative, which lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification \[[@B12]-[@B15]\]. Triple-negative cancers constitute one of the most challenging types of breast cancer, as the only systemic therapy is chemotherapy.

It has been proposed that premenopausal AA women develop triple-negative tumors due to multifactorial differences including socioeconomic factors, body mass index, diet, earlier age at first pregnancy, lower incidence of breastfeeding, and higher breast density \[[@B16],[@B17]\]. However, these factors do not explain everything. A recent study reported that even after adjusting for socioeconomic status, AA women still have a 22% higher mortality rate \[[@B18]\]. Interestingly, there are parallels in carcinoma development between women in western African nations and AAs, including early onset of disease and hormone receptor negativity \[[@B19]\]. These women share common ancestry suggesting that mutations in breast cancer susceptibility genes are partly responsible for the high prevalence of triple-negative carcinomas \[[@B19]\]. This predisposition of AA women to develop a more aggressive cancer compared to CAU women provides a unique model for studying the role of the normal breast microenvironment on breast cancer development. Hence, our objective was to determine whether factors within the local microenvironment of premenopausal AA and CAU women differentially alter the behavior of breast cancer cells.

In this study, premenopausal AA or CAU primary breast fibroblasts and ECM from whole breast tissue were isolated and examined by several *in vitro*and *in vivo*methods. ER^-^/PR^-^cells were significantly more aggressive in the presence of AA ECM by both invasion and soft agar assays; in contrast, CAU ECM caused increased aggressiveness with ER^+^/PR^+^cells. By mass spectrometry, approximately 22% of identified proteins were common to both AA-derived and CAU-derived ECM; proteins related to tumorigenesis/neoplasia were more highly associated with the AA ECM while proteins involved with growth/metastasis were more prevalent with the CAU ECM. Using a novel mass spectrometry assay to measure biologically active hormones, only estradiol, estriol, and 2-methoxyestrone levels were significantly higher in the CAU breast. Finally, in a xenograft model, CAU ECM significantly enhanced the tumorigenicity and metastases of ER^+^/PR^+^cells. To our knowledge, we are the first to investigate the normal ECM of premenopausal women; furthermore, results from this study may help identify mechanisms by which AA are predisposed to developing a more aggressive breast cancer.

Methods
=======

Collection and processing of patient samples
--------------------------------------------

Collection of patient samples was performed in accordance with the guidelines of the National Cancer Institute Review Board, under four separate approved protocol numbers OH99-C-NO57, 02-C-0077E, 04-C-0199, and OHSR4789. Written informed consent was obtained from all human subjects as stipulated in the protocols. Breast tissue was collected from fasting, age-matched, premenopausal AA or CAU reduction mammoplasty patients. The tissue obtained for analyses was considered pathological medical waste; thus any clinical details of the women, apart from age and race, were unattainable. Overall, 53 AA and 50 CAU breast tissue samples, from patients with a median age of 29 years, were used for analyses. Race was self-reported by the patients. Tissue was collected from southern, eastern, and midwestern regions of the US. A pathologist confirmed that each patient was free of malignant or hyperplasic growth. Immediately after surgery a separate piece of tissue was used for isolation of primary human breast fibroblasts, and the remaining tissue was snap frozen and stored at -80°C for RNA and protein analyses, and for ECM isolation.

Pleural effusion cells were collected from a parous, 49-year-old Caucasian breast cancer patient with an ER^+^/PR^+^, Her2^-^, T1, pN1, M1, Grade 3, poorly differentiated invasive ductal carcinoma. Immediately following collection, cells were processed as follows: cells were gently pelleted by centrifugation, washed twice in Hank\'s buffered saline solution, frozen viably in dimethylsulfoxide (DMSO) Freeze media (Invitrogen; Gaithersburg, MD, USA) and stored in liquid nitrogen until used. The cells derived from the pleural effusion were ER^-^/PR^-^and Her2^-^, as determined by immunohistochemistry.

Fluorescent activated cytometric sorting (FACS)
-----------------------------------------------

Immediately prior to use, pleural effusion cells were stained with lineage markers to segregate tumor from non-tumor cells as previously described \[[@B20]\]. Briefly, lineage marker antibodies used were fluorescein conjugated anti-human CD2, CD3, CD10, CD16, CD18, CD31, CD64, and CD140b (BD Biosciences, San Jose, CA, USA). Cells were stained in a phosphate-buffered saline (PBS) solution containing 0.1% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin for 25 min at 4°C. Cell sorting was performed on a BD FACSAria operating at low pressure (20 psi) using a 100 μm nozzle. Doublets were electronically gated out and 7-aminoactinomycin D (7AAD, 1 μg/ml final concentration, BD Biosciences) was used for live/dead cell distinction. Live, fluorescein negative tumor cells were sorted into a PBS solution containing 50% FBS. Post-sort analysis typically indicated purities of \>96% with minimal cell death (\<10%). FACS data were analyzed using FlowJo v8.7.3 (TreeStar, Ashland, OR, USA).

Cell culture
------------

MCF10Ca1h cells (kind gift of FR Miller, Wayne State University, Detroit, MI, USA, through LM Wakefield, Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, USA) were maintained as described previously \[[@B21]\]. All other cell lines were obtained from the American Type Culture Collection (ATCC; <http://www.atcc.org>) and cultured according to the repository\'s instructions. Fibroblasts were isolated as described \[[@B22]\]. Briefly, \<5 mm pieces of tissue were placed on a scratched cell culture dish. Tissue pieces were covered with a minimal amount of media and, with time, the fibroblasts crawled out of the tissue to form a monolayer on the dish. The fragments of tissue were removed and the remaining fibroblasts were passaged and plated as monolayer cultures to expand and ensure fibroblast purity. When necessary, epithelial cells were separated from the stromal cells by differential trypsinization and selective pressure with fibroblast growth medium. Fibroblasts were grown for a maximum of two passages prior to analysis.

Isolation of whole breast tissue ECM proteins
---------------------------------------------

Extraction of human breast ECM from whole breast tissue was performed as previously described \[[@B23]\]. A minimum of three different age-matched patient samples per treatment group was used for each extraction (total n = 26 AA, and 21 CAU). Pools were necessary in order to obtain enough tissue from which to extract ECM. A different pool of samples was used for each experiment. Matrices were stored on ice at 4°C and used within 5 days of isolation.

Zymography
----------

Equal amounts of protein were separated by gel electrophoresis in a 10% Tris-glycine polyacrylamide gel (Invitrogen) with 0.1% gelatin incorporated as a substrate. Proteins were renatured, soaked in developing buffer, and then stained according to the manufacturer\'s instructions. Matrix metalloproteinase (MMP) activity was visualized as clear bands against a dark blue background where the protease has digested the substrate. Identification of MMPs was based on published molecular weights. Three independent experiments, each with different pools of age-matched patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability.

Invasion assay
--------------

Transwell membranes (8 μm pores) were precoated with equal amounts of ECM, adjusted for total protein content. Breast cancer cells were washed, resuspended in serum-free medium, and then plated in the top chamber of transwell inserts (at the predetermined concentration for each cell line). The cells were allowed to invade through the membrane for up to 16 h towards FBS-containing medium in the bottom chamber. Following invasion, the cells were wiped from the top surface of the membrane; the remaining cells were fixed in methanol and stained with a 1% toluidine blue solution. Four independent experiments, each with different pools of patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability.

Soft agar assay
---------------

Breast cancer cells were plated on an 0.66% agarose base in a 0.33% top soft agar layer in 35 mm cell culture dishes with the addition or absence of 100 μl of ECM, adjusted for equal protein content. Cells were incubated for 10 to 12 days, and then stained overnight with nitrobluetetrazolium. The total number of colonies in each dish was counted using the AccuCount 1000 colony counter (BioLogics, Manassas, VA, USA); however, only colonies over 1 μm in diameter were included in the calculation. Three independent experiments, each with different pools of patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability.

Immunohistochemistry
--------------------

Immunohistochemistry was performed with appropriate controls as described previously \[[@B24]\]. Briefly, sections of formalin fixed, paraffin embedded tissue 5 μm thick were prepared from all tumors obtained in the xenograft studies, and fragments of the lungs and livers of animals used in the metastasis experiments. The human specific COXIV antibody (1:1,000, Cell Signaling; Boston, MA, USA) was used for detection of metastases of breast cancer cells in the xenograft experiments. Antibodies Ki67 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and ER (Leica Microsystems, Bannockburn, IL, USA) were used according to manufacturers\' instructions. Staining was performed using Vectastain ABC kit (Vector Laboratories; Burlingame, CA, USA) according to the manufacturer\'s instructions. Color was developed with diaminobenzidine peroxidase substrate kit (Vector Laboratories) and sections were counterstained with hematoxylin.

Quantitative real-time (qRT) PCR and PCR arrays
-----------------------------------------------

Total RNA was isolated from primary breast fibroblasts using the Qiagen RNeasy kit according to the manufacturer\'s instructions (Valencia, CA, USA). RNA was reverse transcribed using MMLV reverse transcriptase (Invitrogen) and primed with oligo-dT and random hexamers (Invitrogen). The cDNA was subjected to RT-PCR amplification using gene specific primers and 2 × Brilliant II Sybr Green QPCR Mastermix (Stratagene, La Jolla, CA, USA). Primer sequences are given in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1. Quantitative RT-PCR was analyzed via the ΔΔCT method, and PCR products were visualized by agarose gel electrophoresis. qRT-PCR arrays were performed and analyzed with the commercially available qRT-PCR array kits according to the manufacturer\'s instructions (SABiosciences, Frederick, MD, USA). Three pools of fibroblasts, each with a minimum of three different patient fibroblasts per pool, were used for each array (n = 9 AA and 10 CAU). Validation of the array data used different, freshly isolated individual primary fibroblasts (n = 9 AA and 9 CAU).

*In vivo*tumor formation assays
-------------------------------

Animal experiments were conducted in accord with accepted standards of humane animal care and approved by the Animal Care and Use Committee at the National Institutes of Health, USA. Female, 8-week-old athymic Nu/Nu mice, or NOD/SCID where indicated, were randomized into three groups with a minimum of five mice per group (APA, Frederick, MD, USA). Mice were anesthetized by an intraperitoneal injection of ketamine/xylazine (750 and 50 mg/kg body weight, respectively) in Hank\'s buffered saline solution (HBSS) prior to surgically exposing the gland for injection. NOD SCID mice were supplemented with estrogen via a subcutaneous pellet (0.72 mg β-estradiol, 90-day release, Innovative Research of America, Sarasota, FL, USA) at the time of breast cancer cell injection. For fibroblast studies, mouse abdominal mammary glands were humanized with primary human fibroblasts as previously described \[[@B25]\]. Each experiment used a minimum of three different patient pools of fibroblasts per humanization (total AA n = 12, CAU n = 14). Following humanization, primary metastatic breast cancer cells, derived from a pleural effusion, were sorted via FACS to remove non-epithelial cells, and then mixed with 1:1 ratio of 1 × PBS:Matrigel (BD Biosciences). A total of 30 μl of ECM containing 5 × 10^3^cells was injected into the humanized abdominal mammary gland fat pad. Tumor growth was measured using calipers on a weekly basis. Tumors were excised when the majority of tumors reach 1.0 cm^3^, and final tumor volume was calculated ((0.5 × L) × (0.5 × W) × (0.5 × H) × (4/3) × (π)).

For ECM studies, breast cancer cells (MDA-MB-231 and T47D) proliferating in log phase were mixed with control matrix (Matrigel), AA or CAU ECM, adjusted for equal protein content. A total of 40 μl of ECM containing 1 × 10^6^or 2 × 10^6^cells was injected, respectively, into the abdominal mammary fat pad or subcutaneously proximal to the scapula. Tumor growth was measured on a weekly basis using calipers. Tumors were excised using survival surgery when the majority of tumors reach 1.0 cm^3^, and final tumor volume was calculated. At 3 months post tumor excision, the animals were killed and the liver and lung tissues were removed for detection of metastases. Tissues were analyzed for metastases by pathological evaluation, quantitative PCR using human-specific primers developed to β2-microglobulin \[[@B26]\], and immunohistochemistry using a human specific COXIV antibody. Each animal experiment was repeated a minimum of two times, using different pools of ECM (minimum of three patients per pool) for each experiment.

Mass spectrometry
-----------------

Three sets of pools of AA and CAU ECM, derived from different patients in each pool, minimum of three patients per pool, were quantified and 2 μg of ECM from each pool were separated on a 4% to 12% Nu-PAGE Bis-Tris gel in MOPS SDS running buffer (Invitrogen). The gel was washed and stained using SimplyBlue Safe Stain Solution (Invitrogen). Each gel lane was divided into 10 sections, excised, destained, lyophilized and digested with trypsin in 25 mM NH~4~HCO~3~, pH 8.4, overnight at 37°C. The tryptic peptides were extracted from gel slices using 70% acetonitrile containing 5% formic acid, lyophilized, and the peptides reconstituted in 0.1% formic acid prior to nanoflow reversed-phase liquid chromatography (nanoRPLC) mass spectrometry analysis. NanoRPLC columns were slurry packed with 5 μm, 300 Å pore size C-18 silica-bonded stationary reverse-phase particles (Jupiter; Phenomenex, Torrance, CA, USA) in a 75 μm internal diameter × 10 cm fused silica capillary with a flame pulled tip. The column was connected to an Agilent 1100 nanoLC system and coupled to a linear ion trap (LIT) mass spectrometer (LTQ, ThermoElectron, , San Jose, CA, USA, operated with Xcalibur 1.4 SR1 software). The samples were injected onto the column and the peptides eluted using a gradient of mobile phase A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile). The LTQ was operated in a data-dependent mode in which the seven most abundant peptide molecular ions in every MS scan were sequentially selected for collision-induced dissociation (CID) using a normalized collision energy of 35%. Dynamic exclusion was applied to minimize repeated selection of peptides previously selected for CID.

Tandem mass spectra were searched against the UniProt human proteomic database from the European Bioinformatics Institute with SEQUEST (http://fields.scripps.edu/sequest/) operating on a 40-node Beowulf cluster. Peptides were searched using fully tryptic cleavage constraints. Oxidation of methionine (+15.9949 Da) was included as dynamic modification. For a peptide to be considered legitimately identified, it must have achieved a minimum Δ correlation (ΔC~n~) of 0.08 and charge state-dependent cross correlation (Xcorr) scores of 1.9 for \[M + H\]^1+^, 2.2 for \[M + 2H\]^2+^, and 3.1 for \[M + 3H\]^3+^peptide molecular ions. Data were subjected to functional analysis through the use of Ingenuity pathways analysis (IPA; Ingenuity Systems, <http://www.ingenuity.com>) and BIOBASE (<http://www.biobase-international.com>).

Estrogen metabolite analysis
----------------------------

### Reagents and materials for steroid analysis

A total of 15 estrogens including estrone (E~1~), estradiol (E~2~), estriol (E~3~), 16-epiestriol (16-epiE~3~), 17-epiestriol (17-epiE~3~), 16-ketoestradiol (16-ketoE~2~), 16α-hydroxyestrone (16α-OHE~1~), 2-methoxyestrone (2-MeOE~1~), 4-methoxyestrone (4-MeOE~1~), 2-hydroxyestrone-3-methyl ether (3-MeOE~1~), 2-methoxyestradiol (2-MeOE~2~), 4-methoxyestradiol (4-MeOE~2~), 2-hydroxyestrone (2-OHE~1~), 4-hydroxyestrone (4-OHE~1~), and 2-hydroxyestradiol (2-OHE~2~) and 2 androgens, androstenedione and testosterone, were obtained from Steraloids (Newport, RI, USA). Stable isotope labeled steroids, including estradiol-13,14,15,16,17,18-^13^C~6~(^13^C~6~-E~2~) and estrone-13,14,15,16,17,18-^13^C~6~(^13^C~6~-E~1~) were purchased from Cambridge Isotope Laboratories (Andover, MA, USA); estriol-2,4,17-*d*~3~(d~3~-E~3~), 2-hydroxyestradiol-1,4,16,16,17-*d*~5~(d~5~-2-OHE~2~), 2-methoxyestradiol-1,4,16,16,17-*d*~5~(d~5~-2-MeOE~2~), androstenedione-2,2,4,6,6,16,16-*d*~7~and testosterone-16,16,17-*d*~3~were obtained from C/D/N Isotopes (Pointe-Claire, Quebec, Canada). 16-Epiestriol-2,4,16-*d*~3~(d~3~-16-epiE~3~) was purchased from Medical Isotopes (Pelham, NH, USA). All steroid analytical standards have reported chemical and isotopic purity ≥98%, and were used without further purification. Dichloromethane and methanol were obtained from EM Science (Gibbstown, NJ, USA). Glacial acetic acid and sodium bicarbonate were purchased from JT Baker (Phillipsburg, NJ, USA) and sodium hydroxide and sodium acetate were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ethyl alcohol was obtained from Pharmco Products (Brookfield, CT, USA). Formic acid, acetone, dansyl chloride, and L-ascorbic acid were obtained from Sigma-Aldrich (St Louis, MO, USA). All chemicals and solvents used in this study were high performance liquid chromatography (HPLC) or reagent grade unless otherwise noted.

### Preparation of stock and working standard solutions

Stock solutions of steroids and stable isotope labeled steroids were each prepared at 80 μg/ml by dissolving 2 mg of each estrogen powder in methanol containing 0.1% [l]{.smallcaps}-ascorbic acid to a final volume of 25 ml in a volumetric flask. Stock solutions were monitored by measuring the absolute peak height of each steroid using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) to verify that no time-dependent degradation of steroid standards had occurred. The stock solutions are stable for at least 2 months while stored at -20°C. Working standard solutions of steroids at 0.32 and 8.0 ng/ml were prepared by dilutions of the stock solutions with methanol containing 0.1% [l]{.smallcaps}-ascorbic acid.

### Sample preparation procedure

To quantitatively measure unconjugated biologically active estrogen metabolites (EM) and androgens, breast tissue samples (0.2-0.3 g per patient) were thawed briefly at room temperature, minced with scissors, and transferred into 1.5 ml Eppendorf tubes. A total of 19 AA patient samples and 20 CAU samples were analyzed. The tissue was hardened by snap freezing in liquid nitrogen for 5 min, pulverized and then transferred into a clean screw-capped glass tube containing 1 ml of ice-cold 12.5 mM NH~4~HCO~3~buffer. The tissue was homogenized on ice using a Tissue Tearor (Cole-Parmer, Vernon Hills, IL, USA) at low and high speed in two consecutive 15 s segments for a total of 30 s, and further sonicated on ice for five cycles of 10 s pulses with 10 s breaks in between pulses. Then, 8 ml of ethanol:acetone and 50 μl each of stable isotope-labeled estrogen and androgen internal standards (0.32 ng/ml working standard solutions) were added to each tissue homogenate. The mixture was incubated on a rotator at room temperature for 1 h and centrifuged at 3,000 *g*for 30 min. The ethanol:acetone tissue extract was transferred to a clean glass tube and dried under nitrogen gas at 60°C for 1 h (Reacti-Vap III, Pierce, Rockford, IL, USA). The residue was redissolved in 4 ml of methanol, vortexed for 1 min, chilled at -80°C for 1 h, returned to room temperature and then centrifuged at 3,000 *g*for 20 min. The methanolic phase was transferred to a clean glass tube and dried under nitrogen gas. The residue was further redissolved in 100 μl of ethanol and vortexed briefly. This was followed by the addition of 1.5 ml of 100 mM sodium acetate buffer, pH 4.6 and 5 ml of dichloromethane to the residue, and incubation at room temperature on a rotator for 30 min. The extract was chilled at -80°C for 10 min, returned to room temperature and centrifuged at 3,000 *g*for 20 min. The dichloromethane phase was transferred to a clean tube and dried. To each dried sample, 32 μl of 0.1 M sodium bicarbonate buffer, pH 9.0, and 32 μl of dansyl chloride solution (1 mg/ml in acetone) were added. After vortexing for 10 s, samples were heated at 70°C (Reacti-Therm III Heating Module; Pierce) for 10 min to form the EM and d-EM dansyl derivatives. The dansyl derivatization method modifies the phenol hydroxyl group of EM and will not react with testosterone. After derivatization, all samples were centrifuged at 3,000 *g*for 20 min, and analyzed by the capillary LC-ESI-MS/MS.

### Capillary liquid chromatography-electrospray ionization tandem mass spectrometry analysis (Cap LC-ESI-MS/MS)

Capillary LC-ESI-MS/MS analysis was performed using an Agilent 1200 series nanoflow LC system (Agilent Technologies, Palo Alto, CA, USA) coupled to a TSQ Quantum Ultra triple quadrupole mass spectrometer (ThermoElectron). The LC separation was carried out on a 150 mm long × 300 μm internal diameter column packed with 4 μm Synergi Hydro-RP particles (Phenomenex) and maintained at 40°C. A total of 8.0 μl of each sample was injected onto the column. The mobile phase, operating at a flow rate of 4.0 μl/min, consisted of methanol as solvent A and 0.1% (v/v) formic acid in water as solvent B. A linear gradient increasing from 72% to 85% solvent A in 75 min was employed for the separation. The MS conditions were source: ESI; ion polarity: positive; spray voltage: 3,500 V; sheath and auxiliary gas: nitrogen; sheath gas pressure: 7 arbitrary units; ion transfer capillary temperature, 270°C; scan type: selected reaction monitoring (SRM); collision gas: argon; collision gas pressure: 1.5 mTorr; scan width: 0.7 u; scan time: 0.50 s; Q1 peak width: 0.70 u full-width half-maximum (FWHM); Q3 peak width: 0.70 u FWHM. The specific SRM transitions of protonated androgens were: testosterone *m/z*289→97 and 109; testosterone-*d*~3~*m/z*292→97 and 109; androstenedione *m/z*287→97 and 109; androstenedione-*d*~7~*m/z*287→100 and 113.

Quantitation of tissue estrogens and androgens
----------------------------------------------

Quantitation of tissue estrogens and androgens was carried out using Xcalibur Quan Browser (ThermoElectron). Briefly, calibration curves for each steroid were constructed by plotting non-labeled steroid/stable isotope labeled steroid peak area ratios obtained from calibration standards versus amounts of the steroid injected on the column and fitting these data using linear regression with 1/X weighting. The amounts of steroid in the tissue were then interpolated using this linear function.

Statistical analysis
--------------------

Pools of patient samples were necessary to obtain the required amount of tissue for ECM extraction. When appropriate, data was evaluated for significance via two-tailed Student t tests, repeated measures analysis of variance (ANOVA) with the Bonferroni multiple comparisons *post hoc*analysis, Wilcoxon matched pairs, or Mann-Whitney tests using GraphPad InStat Software version 3.0b (San Diego, CA, USA). Data was considered significant at *P*\< 0.05.

Results
=======

Effects of premenopausal breast fibroblasts on breast cancer cell tumorigenicity
--------------------------------------------------------------------------------

It has previously been shown that tumor-derived fibroblasts promote, while normal fibroblasts inhibit, the growth of tumorigenic epithelial cells *in vitro*and *in vivo*\[[@B7],[@B27]\]. Therefore, we first \'humanized\' the mouse mammary gland \[[@B27]\] creating a microenvironment with supportive stromal components from either the AA or CAU breast. Primary breast fibroblasts from age-matched, premenopausal women were isolated \[[@B22]\] and a pool of a minimum of three patient-derived fibroblasts per group was injected into mouse abdominal mammary glands. A different pool of patient fibroblasts was used for each of three independent humanization experiments. As shown in Figure [1a](#F1){ref-type="fig"}, both the AA and CAU fibroblasts equally humanized the glands, suggesting that the source of the fibroblasts did not have an effect on the percentage of growth throughout the glands.

![**Tumor formation and extracellular matrix molecules (ECM)/cytokine analyses of premenopausal African-American and Caucasian-American breast fibroblasts**. **(a)**Hematoxylin and eosin (H&E) staining of murine mammary glands humanized with African-American (AA) or Caucasian-American (CAU) fibroblasts. **(b,c)**Humanized murine mammary glands were injected with either primary metastatic breast cancer or T47D cells. Data represent mean ± SD of final tumor volume. **(d,e)**Quantitative real-time PCR analysis: primary human breast fibroblasts were isolated from fresh reduction mammoplasty breast tissue. RNA was isolated and analyzed via quantitative real-time PCR. Individual patient samples (*n*= 18) were used to validate array results with newly designed primers to the indicated genes. Data represent fold increase ± standard error of differentially regulated genes. \**P*\< 0.05](1741-7015-8-27-1){#F1}

Following humanization, primary metastatic breast cancer cells (ER^-^/PR^-^, as described in Methods) were injected into the glands. Injection of breast cancer cells into the humanized glands was repeated in two independent experiments using different pools of patient-derived normal breast fibroblasts; however, the same breast cancer patient sample was used specifically to minimize any confounding effects of the relatively uncharacterized primary breast cancer cells. For all treatments tested, the tumor incidence was 100%, with no obvious morphological differences between treatment groups; tumors were ER^-^/PR^-^, undifferentiated invasive carcinomas. Interestingly, glands humanized with CAU fibroblasts repeatedly developed significantly larger tumors compared to AA humanized glands (Figure [1b](#F1){ref-type="fig"}, *P*\< 0.008) suggesting that either CAU fibroblasts were more permissive to tumorigenesis, or that AA fibroblasts were more restrictive. There was no significant difference in the Ki67 proliferation index at the time of tumor collection (Additional file [1](#S1){ref-type="supplementary-material"}, Figure S1a). Additionally, of the tumors that contained necrotic regions, there was no significant difference in the percentage of necrotic area; however, it should be noted that the significantly larger tumors from glands humanized with CAU fibroblasts had overall higher levels of tumors containing necrotic regions compared to the AA humanized glands (50% vs 33%, Additional file [1](#S1){ref-type="supplementary-material"}, Figure S1b).

A similar pattern of tumor formation was observed using T47D, a well characterized, ER^+^/PR^+^human breast cancer cell line; the cells injected into the glands humanized with the CAU fibroblasts had increased tumor volume (Figure [1c](#F1){ref-type="fig"}, *P*\< 0.05). The resultant tumors from both treatment groups were ER^+^/PR^+^by immunohistochemistry (data not shown); therefore the hormonal status of the cells was retained regardless of the source of fibroblasts.

In the presence of fibroblasts derived from the two groups, differences in tumorigenicity were observed. Therefore, the expression profiles of 164 ECM molecules and cytokines were examined using qRT-PCR arrays. Cytokines were analyzed since components of the immune system have been reported to modulate the initiation and progression of breast cancer, including metastasis to bone \[[@B28]-[@B32]\]. Fibroblasts were expanded in culture for less than two passages prior to isolation of total RNA. Different pools of at least three patient samples per group were used in each of three independent array experiments (n = 9 AA, n = 10 CAU). A set of ECM proteins and cytokines was consistently differentially regulated between the two groups (Additional file [1](#S1){ref-type="supplementary-material"}, Figure S2a and b, respectively). Array results were validated by qRT-PCR; expression patterns were observed not only using samples from the array analysis, but also with additional randomly chosen, freshly isolated, individual patient samples (n = 18, Figure [1d, e](#F1){ref-type="fig"}). As expected, there was substantial individual patient variation; however, 13 of the 18 genes that were differentially expressed between the groups in the array analysis were significantly different when individual patient samples were analyzed (*P*\< 0.05). Of note, CAU-derived fibroblasts repeatedly exhibited an increase in cytokine expression (Figure [1e](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}, Figure S2b). This observation may explain, in part, the increase in tumor growth observed in the xenograft experiments (Figure [1b, c](#F1){ref-type="fig"}). Collectively, these data suggest that when stromal fibroblasts are confronted with the invasion of tumorigenic breast cells, genetic variation between the groups differentially affected tumorigenesis via the production of distinctive ECM molecules and cytokines.

Effects of premenopausal breast ECM on breast cancer cells *in vitro*
---------------------------------------------------------------------

Numerous cell types, in addition to fibroblasts, comprise the breast microenvironment. To gain further insight into these multicellular interactions, we analyzed a broader spectrum of molecules within the breast by isolating ECM proteins from premenopausal whole breast tissue. In order to test whether ECM isolated from whole breast tissue was able to differentially influence breast cancer cell aggressiveness, we examined cell motility and invasiveness using transwell filter assays. Two classes of breast cancer cell lines were used: ER^-^/PR^-^(MDA-MB-231, SUM159, MCF10Ca1h) and ER^+^/PR^+^(T47D, MCF7, BT474). These cell lines were chosen for their well characterized phenotype, specifically to limit any confounding effects of uncharacterized primary breast cancer cells. Cells were overlaid onto one of the three matrices (adjusted for equal protein concentration) and allowed to respond to a chemoattractant. Four independent experiments, each with different pools of patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability. Cell invasion through the control matrix was low for all cell lines tested (Figure [2a](#F2){ref-type="fig"}). Interestingly, the ability of cells to invade through the ECM was dependent upon both the cell\'s hormone receptor status and the source of the ECM. The ER^-^/PR^-^cells were consistently more invasive when in contact with the AA ECM. Conversely, all of the ER^+^/PR^+^cell lines tested were more invasive when in contact with the CAU ECM, suggesting that the invasiveness of cells was enhanced by a hormone receptor-dependent mechanism in the presence of CAU ECM. The increased invasiveness may have occurred through a combinatorial effect of ECM components and hormones in the chemoattractant serum. This potential hormone receptor-dependent stimulus had no effect on the ER^-^/PR^-^cells. In the AA-derived ECM, however, a hormone-independent mechanism appeared to further stimulate the invasiveness of the ER^-^/PR^-^cells.

![**Invasion and anchorage-independent growth of breast cancer cells in the presence of premenopausal African-American or Caucasian-American breast extracellular matrix molecules (ECM)**. **(a)**Cell invasion through transwell inserts, precoated with equal amounts of ECM. Data are representative of four independent experiments. **(b)**Soft agar assays. Cells were stained with nitrobluetetrazolium before counting after 10 days of growth. The entire dish was analyzed and colonies larger than 1 μm in diameter were counted. Data represent mean ± standard error of three separate experiments. \**P*\< 0.05 \*\**P*\< 0.01, \*\*\**P*\< 0.001; paired t test. **(c)**Gelatin zymography. ECM was isolated from six pools of 3-7 patients/pool. Results are representative of three experiments performed in triplicate. AA = African-American; CAU = Caucasian-American.](1741-7015-8-27-2){#F2}

Soft agar transformation assays were performed to measure whether the addition of either ECM could differentially influence cell survival under anchorage-independent conditions, mimicking changes that occur during tumorigenesis. Results were similar to those observed with invasion assays; the AA ECM significantly increased the number of colonies for the ER^-^/PR^-^MDA-MB-231 cells above all other treatments (*P*\< 0.01, Figure [2b](#F2){ref-type="fig"}). Similar results were observed with SUM159 and MCF10Ca1h cells (Additional file [1](#S1){ref-type="supplementary-material"}, Figure S3). Additionally, the CAU ECM significantly increased colony formation above untreated controls for the ER^+^/PR^+^T47D cell line (*P*\< 0.05 Figure [2b](#F2){ref-type="fig"}, similarly for MCF7, ZR75-1, and BT474 cells; Additional file [1](#S1){ref-type="supplementary-material"}, Figure S3). Thus, the ability of the cells to survive and proliferate in hostile, anchorage-independent conditions appeared dependent upon both the source of the ECM and the hormonal status of the cells.

To further analyze the composition of the whole breast ECM, we assessed its protease activity. The stroma can act as a reservoir for matrix metalloproteinases (MMPs), which degrade ECM proteins and process a number of bioactive molecules. In breast tissue, MMP activity contributes to epithelial cell death, influences tissue remodeling, and has been implicated in cancer invasion and metastasis \[[@B33]-[@B35]\]. Gelatin zymography was employed, and in multiple experiments the protease activity of at least two different MMPs was upregulated in the CAU compared to the AA ECM as determined using gelatin zymography (representative gel; Figure [2c](#F2){ref-type="fig"}). When compared to the fibroblast PCR array analysis, there was no significant increase in MMP expression in the CAU fibroblasts compared to the AA, indicating that cells other than fibroblasts produce MMPs, or that there is increased stimulation of MMP activity in CAU versus AA ECM.

Effects of ECM on tumorigenicity *in vivo*
------------------------------------------

We sought to address whether factors within the breast ECM, removed from the physical presence of stromal cells, could affect the tumorigenicity of breast cancer cells *in vivo*. As described by McDaniel *et al.*\[[@B26]\], ER^-^/PR^-^MDA-MB-231 or ER^+^/PR^+^T47D breast cancer cells were mixed with control matrix (Matrigel), AA or CAU ECM (adjusted for equal protein content) and injected into the abdominal mammary fat pad of female, athymic nude mice. No significant difference in tumor efficiency was observed among the treatments (Figure [3a](#F3){ref-type="fig"}). However, the CAU ECM significantly increased tumor growth of the ER^+^/PR^+^T47D cells compared to either the AA ECM or control matrix control (Figure [3b](#F3){ref-type="fig"}; *P*\< 0.01 and 0.05, respectively). AA ECM elicited no difference in growth compared to the control matrix. The resultant T47D tumors from all treatment groups were ER^+^; confirming that hormone status of the cells was retained during tumor formation (data not shown). Tumor morphology and percentage necrosis were similar between treatments. These data support the observation that factors within CAU ECM selectively interact with ER^+^/PR^+^cells to increase their aggressiveness. The *in vitro*data demonstrating enhanced MMP activity and increased cytokine production in the CAU microenvironment could potentially account for this increase in tumor growth.

![**Caucasian-American derived extracellular matrix molecules (ECM) enhances the tumorigenicity of estrogen receptor (ER)**^**+**^**/progesterone receptor (PR)^+^breast cancer cells**. **(a)**Indicates the number of tumors detected per animals injected. **(b,c)**Data represent mean ± SD of the final tumor volume of ER^+^/PR^+^(T47D) or ER^-^/PR^-^(MDA-MB-231) breast cancer cells suspended in the indicated ECM and injected into the abdominal mammary gland. **(d)**Data represent mean ± SD of the final tumor volume of MDA-MB-231 breast cancer cells suspended in the indicated ECM and injected subcutaneously. AA = African-American, CAU = Caucasian-American.](1741-7015-8-27-3){#F3}

Conversely, injecting ER^-^/PR^-^MDA-MB-231 cells with ECM derived from either group gave no selective advantage in tumor growth. Only cells injected with growth factor-rich control matrix had significantly increased final tumor volume (*P*\< 0.05, Figure [3c](#F3){ref-type="fig"}). To confirm that the ECM\'s effect on tumorigenicity was not masked due to interactions with the host mammary gland, MDA-MD-231 cells were mixed with control matrix, AA or CAU ECM, adjusted for equal protein content, and injected subcutaneously into athymic nude mice. A similar trend to results obtained from the orthotopic site was observed. Only cells injected with the control matrix had substantially larger final tumor volume compared to cells injected with ECM derived from either group, although no statistically significant difference was observed between either ECM (Figure [3d](#F3){ref-type="fig"}). No significant difference in tumor latency was observed among the treatments.

Metastasis to the lung and liver was low for all treatments and cell lines tested. Of the 75 lung samples analyzed, only 18 tested positive for lung metastasis via pathological examination, immunohistochemical analysis for human specific COXIV, and qRT-PCR for human β2-microglobin \[[@B26]\] (Figure [4](#F4){ref-type="fig"}). No liver metastases were found by histological examination. Regardless of the cell type injected, the CAU ECM elicited at least twice the metastases as AA ECM (Figure [4a](#F4){ref-type="fig"}). Figure [4c](#F4){ref-type="fig"} depicts representative images of hematoxylin and eosin (H&E)-stained lungs with overt metastases resulting from the two cell types, and metastatic cells within the lung were detected by a human specific COXIV antibody (Figure [4d](#F4){ref-type="fig"}). No correlation between the size of the primary tumor and metastasis and no significant difference between the amount of metastasis and treatment was observed for all samples analyzed.

![**Caucasian-American extracellular matrix molecules (ECM) enhances metastasis to lung**. **(a)**Number of animals positive for lung metastasis per animals injected. **(b)**Ethidium bromide stained gel of PCR products; RNA was analyzed by quantitative real-time PCR for lung metastasis using human-specific primers to β2 microglobulin. C = control human cDNA; L = mouse lung cDNA; NTC = no template control. **(c)**Representative hematoxylin and eosin (H&E)-stained mouse lungs with human breast cancer cell metastasis. **(d)**Immunohistochemical detection of metastasized cells with the human-specific antibody COXIV (left panels) or corresponding negative controls (right panels) in mouse lung. Scale bar = 50 μM. AA = African-American, CAU = Caucasian-American.](1741-7015-8-27-4){#F4}

Mass spectrometry analysis of the ECM
-------------------------------------

To determine whether the overall composition of the ECM differed between premenopausal AAs and CAUs, breast ECM proteins were intimately examined by LC-MS/MS. Three independent ECM extraction experiments, using different patient samples for each experiment, with at least three patients per group, (that is, a total of six individual ECM pools) were analyzed using LC-MS/MS. Among the 4,288 AA and 4,301 CAU proteins identified, only 1,759 were common between the groups. Ingenuity pathways analysis (IPA, Ingenuity Systems, <http://www.ingenuity.com>) was used for functional analysis of the results. The majority of the high abundance proteins (≥30 peptide matches) consisted of structural ECM proteins including numerous collagen species. These were comparatively similar for either group. Therefore, we excluded those identified by ≥30 peptides to focus on those with lower abundance. Additionally, although it is possible to identify a protein from a single peptide match after careful inspection of the fragment\'s pattern and other characteristics, we excluded these single unique peptides and focused our studies on those above two peptide matches. During analysis, proteins reported to be exclusively nuclear were excluded as cellular contamination (23.4% for the AA dataset and 23.0% for the CAU dataset). In addition to ECM structural proteins, another distinct feature of the microenvironment is the presence of extracellular matrix vesicles (MV) and exosomes, small sacs secreted from the cell surface which are enclosed by a membrane structurally similar to that of the plasma membrane \[[@B36]\]. Molecules located within MV/exosomes perform diverse functions outside of the cell including growth factor storage and secretion, immune regulation, ECM mineralization, and RNA shuttling. Interestingly, tumor-associated MV/exosomes have been shown to contribute to the ability of tumor cells to escape immune surveillance, degrade ECM to facilitate invasion, and stimulate angiogenesis \[[@B36]\]. Therefore, no cytosolic proteins that may have been released into the ECM by MV/exosomes were excluded. Representative western blot images of four randomly chosen proteins were selected for validation of LC-MS/MS analysis with their corresponding numbers of peptides identified (Figure [5a](#F5){ref-type="fig"}, representative spectra shown in Additional file [1](#S1){ref-type="supplementary-material"}, Figure S4).

![**Proteomic analysis of African-American and Caucasian-American breast extracellular matrix molecules (ECM)**. **(a)**Western blot of proteins identified by mass spectrometry with corresponding identified peptides. **(b)**Datasets of proteins unique to African-American or Caucasian-American ECM grouped according to significant association to canonical pathways. B-H = Benjamini-Hochberg. **(c)***In silico*analysis of proteins: top signaling network of proteins unique to the African-American (left) or Caucasian-American (right) datasets. AA = African-American, CAU = Caucasian-American.](1741-7015-8-27-5){#F5}

Pathways analyses by IPA revealed that the actin cytoskeleton signaling and the hepatic fibrosis/hepatic stellate cell activation pathways were only significant for the AA dataset, based on a strict *P*value threshold of 0.005 and Benjamini-Hochberg correction (Figure [5b](#F5){ref-type="fig"}). Both of these pathways, as well as tight junction signaling and regulation of actin-based motility by Rho, had numerous molecules in common including Rho-associated kinase (ROCK), actin, and several myosins. The significant presence of these pathways in only the AA microenvironment implies unique cytoskeletal signaling compared to that in CAU.

To further examine differences among datasets, we analyzed networks created by proteins found exclusively in the AA or the CAU datasets. The network with the highest score for the AA dataset contained seven nodes representing proteins/genes associated with tight junction signaling and actin cytoskeleton signaling pathway (Figure [5c](#F5){ref-type="fig"}). The top network generated by the CAU dataset contained several other adhesion molecules and the epidermal growth factor receptor ErbB3, which is known to promote epithelial cell growth and antiapoptotic signaling. ErbB3 is often overexpressed in human breast cancers, frequently in conjunction with overexpression of the proto-oncogene ErbB2/HER2 \[[@B37]\]. Interestingly, the CAU dataset also contained molecules associated with the Wnt/β-catenin pathway (Figure [5c](#F5){ref-type="fig"}), whose dysregulation has been implicated in breast cancer development and progression \[[@B38]\]. Additional networks for the AA can CAU datasets can be found in Additional file [1](#S1){ref-type="supplementary-material"}, Figures S5a-d and S6a-d.

Based on annotations by two manually curated databases (IPA and BIOBASE, <http://www.biobase-international.com>), similar and unique proteins to each dataset, and their known associations with breast cancer, were examined. The AA and CAU datasets had 52 common molecules (Table [1](#T1){ref-type="table"}) and 48 and 47 unique proteins, respectively (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Further functional analyses of these proteins indicated that the AA dataset were mainly related to initiation events, including tumorigenesis and neoplasia. Alternatively, the proteins unique to the CAU dataset were primarily involved with tumor growth or metastasis.

###### 

Proteins found in both African-American and Caucasian-American datasets reported to be involved in breast cancer, as annotated by Ingenuity Systems or BIOBASE.

  Symbol     Entrez gene name                                                              Location              Entrez gene ID
  ---------- ----------------------------------------------------------------------------- --------------------- ----------------
  ABCC4      ATP-binding cassette, sub-family C (CFTR/MRP), member 4                       Plasma membrane       10257
  ACTA2      Actin, alpha 2, smooth muscle, aorta                                          Cytoplasm             59
  ACTB       Actin, beta                                                                   Cytoplasm             60
  ADAMTS15   ADAM metallopeptidase with thrombospondin type 1 motif, 15                    Extracellular space   170689
  ADRA1B     Adrenergic, alpha-1B-, receptor                                               Plasma membrane       147
  ANXA2      Annexin A2                                                                    Plasma membrane       302
  APOB       Apolipoprotein B (including Ag(x) antigen)                                    Extracellular space   338
  APOD       Apolipoprotein D                                                              Extracellular space   347
  ATP5B      ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide     Cytoplasm             506
  AXL        AXL receptor tyrosine kinase                                                  Plasma membrane       558
  C3         Complement component 3                                                        Extracellular space   718
  CAV1       Caveolin 1, caveolae protein, 22 kDa                                          Plasma membrane       857
  CNR2       Cannabinoid receptor 2 (macrophage)                                           Plasma membrane       1269
  COL18A1    Collagen, type XVIII, alpha 1                                                 Extracellular space   80781
  CYP2C9     Cytochrome P450, family 2, subfamily C, polypeptide 9                         Cytoplasm             1559
  DCD        Dermcidin                                                                     Extracellular space   117159
  DSP        Desmoplakin                                                                   Plasma membrane       1832
  FES        Feline sarcoma oncogene                                                       Cytoplasm             2242
  FN1        Fibronectin 1                                                                 Plasma membrane       2335
  GART       Phosphoribosylglycinamide formyltransferase/synthetase,                       Cytoplasm             2618
  GFRA1      GDNF family receptor alpha 1                                                  Plasma membrane       2674
  HSPA5      Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)               Cytoplasm             3309
  HSPG2      Heparan sulfate proteoglycan 2                                                Plasma membrane       3339
  IGF2R      Insulin-like growth factor 2 receptor                                         Plasma membrane       3482
  IGKC       Immunoglobulin kappa constant                                                 Extracellular space   3514
  ITGA2      Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)                  Plasma membrane       3673
  JUP        Junction plakoglobin                                                          Plasma membrane       3728
  LAMA3      Laminin, alpha 3                                                              Extracellular space   3909
  LDHA       Lactate dehydrogenase A                                                       Cytoplasm             3939
  LEPR       Leptin receptor                                                               Plasma membrane       3953
  LGALS1     Lectin, galactoside-binding, soluble, 1                                       Extracellular space   3956
  MAGED1     Melanoma antigen family D, 1                                                  Plasma membrane       9500
  MAP3K4     Mitogen-activated protein kinase kinase kinase 4                              Cytoplasm             4216
  MUC16      Mucin 16, cell surface associated                                             Extracellular space   94025
  MUC5AC     Mucin 5AC, oligomeric mucus/gel-forming                                       Extracellular space   4586
  NF1        Neurofibromin 1                                                               Cytoplasm             4763
  PCM1       Pericentriolar material 1                                                     Cytoplasm             5108
  POSTN      Periostin, osteoblast specific factor                                         Extracellular space   10631
  PRDX3      Peroxiredoxin 3                                                               Cytoplasm             10935
  PRKCG      Protein kinase C, gamma                                                       Cytoplasm             5582
  PRLR       Prolactin receptor                                                            Plasma membrane       5618
  PTN        Pleiotrophin                                                                  Extracellular space   5764
  PTPN13     Protein tyrosine phosphatase, non-receptor type 13                            Cytoplasm             5783
  PXDN       Peroxidasin homolog (Drosophila)                                              Unknown               7837
  SERPINA1   Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin) 1   Extracellular space   5265
  SLC16A3    Solute carrier family 16, member 3 (monocarboxylic acid transporter 4)        Plasma membrane       9123
  SLC19A1    Solute carrier family 19 (folate transporter), member 1                       Plasma membrane       6573
  TES        Testis derived transcript (3 LIM domains)                                     Plasma membrane       26136
  TNC        Tenascin C                                                                    Extracellular space   3371
  TUBA1A     Tubulin, alpha 1a                                                             Cytoplasm             7846
  VCL        Vinculin                                                                      Plasma membrane       7414
  VTN        Vitronectin                                                                   Extracellular space   7448

###### 

Proteins found unique to the African-American dataset that are reported to be involved in breast cancer, as annotated by Ingenuity Systems or BIOBASE.

  Symbol     Entrez gene name                                                             Location              Entrez gene ID
  ---------- ---------------------------------------------------------------------------- --------------------- ----------------
  ADAM12     ADAM metallopeptidase domain 12                                              Plasma membrane       8038
  ADRA2C     Adrene gic, alpha-2C-, receptor                                              Plasma membrane       152
  AKR1C1     Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1)        Cytoplasm             1645
  ANK1       Ankyrin 1, erythrocytic                                                      Plasma membrane       286
  ANXA1      Annexin A1                                                                   Plasma membrane       301
  ANXA5      Annexin A5                                                                   Plasma membrane       308
  BCAS1      Breast carcinoma amplified sequence 1                                        Unknown               8537
  CAMKK1     Calcium/calmodulin-dependent protein kinase kinase 1, alpha                  Cytoplasm             84254
  CANX       Calnexin                                                                     Cytoplasm             821
  CASP1      Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, convertase   Cytoplasm             834
  CD69       CD69 molecule                                                                Plasma membrane       969
  CDH11      Cadherin 11, type 2, OB-cadherin (osteoblast)                                Plasma membrane       1009
  CDR2       Cerebellar degeneration-related protein 2, 62 kDa                            Cytoplasm             1039
  CTSD       Cathepsin D                                                                  Cytoplasm             1509
  DAB2       Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)           Plasma membrane       1601
  DECR1      2,4-Dienoyl CoA reductase 1, mitochondrial                                   Cytoplasm             1666
  DFNA5      Deafness, autosomal dominant 5                                               Unknown               1687
  DLC1       Deleted in liver cancer 1                                                    Cytoplasm             10395
  EDNRB      Endothelin receptor type B                                                   Plasma membrane       1910
  EEF1A1     Eukaryotic translation elongation factor 1 alpha 1                           Cytoplasm             1915
  ERBB4      V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)             Plasma membrane       2066
  FBLN1      Fibulin 1                                                                    Extracellular space   2192
  GAPDH      Glyceraldehyde-3-phosphate dehydrogenase                                     Cytoplasm             2597
  GRIN2D     Glutamate receptor, ionotropic, *N*-methyl [d]{.smallcaps}-aspartate 2D      Plasma membrane       2906
  GSN        Gelsolin (amyloidosis, Finnish type)                                         Extracellular space   2934
  HSPB1      Heat shock 27 kDa protein 1                                                  Cytoplasm             3315
  IGF1R      Insulin-like growth factor 1 receptor                                        Plasma membrane       3480
  KDR        Kinase insert domain receptor (a type III receptor tyrosine kinase)          Plasma membrane       3791
  LTF        Lactotransferrin                                                             Extracellular space   4057
  MET        Met proto-oncogene (hepatocyte growth factor receptor)                       Plasma membrane       4233
  MMP14      Matrix metallopeptidase 14 (membrane-inserted)                               Extracellular space   4323
  MUC6       Mucin 6, oligomeric mucus/gel-forming                                        Extracellular space   4588
  NLRP1      NLR family, pyrin domain containing 1                                        Cytoplasm             22861
  ORM1       Orosomucoid 1                                                                Extracellular space   5004
  PDGFRB     Platelet-derived growth factor receptor, beta polypeptide                    Plasma membrane       5159
  PLXNA1     Plexin A1                                                                    Plasma membrane       5361
  POR        P450 (cytochrome) oxidoreductase                                             Cytoplasm             5447
  PTPRG      Protein tyrosine phosphatase, receptor type, G                               Plasma membrane       5793
  ROCK1      Rho-associated, coiled-coil containing protein kinase 1                      Cytoplasm             6093
  S100A9     S100 calcium binding protein A9                                              Cytoplasm             6280
  SERPINA3   Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase), member 3       Extracellular space   12
  SERPINB5   Serpin peptidase inhibitor, clade B (ovalbumin), member 5                    Extracellular space   5268
  SOD1       Superoxide dismutase 1, soluble                                              Cytoplasm             6647
  SOD2       Superoxide dismutase 2, mitochondrial                                        Cytoplasm             6648
  SYK        Spleen tyrosine kinase                                                       Cytoplasm             6850
  TAGLN      Transgelin                                                                   Cytoplasm             6876
  TJP1       Tight junction protein 1 (zona occludens 1)                                  Plasma membrane       7082
  TXNRD1     Thioredoxin reductase 1                                                      Cytoplasm             7296

###### 

Proteins found unique to the Caucasian-American dataset that are reported to be involved in breast cancer, as annotated by Ingenuity Systems or BIOBASE.

  Symbol     Entrez gene name                                                                              Location              Entrez gene ID
  ---------- --------------------------------------------------------------------------------------------- --------------------- ----------------
  ABCC5      ATP-binding cassette, sub-family C (CFTR/MRP), member 5                                       Plasma membrane       10057
  ACE        Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1                                    Plasma membrane       1636
  BCAR3      Breast cancer anti-estrogen resistance 3                                                      Cytoplasm             8412
  CDON       Cdon homolog (mouse)                                                                          Plasma membrane       50937
  CLCA2      CLCA family member 2, chloride channel regulator                                              Plasma membrane       9635
  CSF1R      Colony stimulating factor 1 receptor                                                          Plasma membrane       1436
  CTGF       Connective tissue growth factor                                                               Extracellular space   1490
  DAPK1      Death-associated protein kinase 1                                                             Cytoplasm             1612
  DLG5       Discs, large homolog 5 (Drosophila)                                                           Plasma membrane       9231
  ERBB3      V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)                             Plasma membrane       2065
  FRZB       Frizzled-related protein                                                                      Extracellular space   2487
  GREB1      GREB1 protein                                                                                 Cytoplasm             9687
  HGF        Hepatocyte growth factor (hepapoietin A; scatter factor)                                      Extracellular space   3082
  HPN        Hepsin (transmembrane protease, serine 1)                                                     Plasma membrane       3249
  HSPA8      Heat shock 70 kDa protein 8                                                                   Cytoplasm             3312
  IL17RB     Interleukin 17 receptor B                                                                     Plasma membrane       55540
  IRS2       Insulin receptor substrate 2                                                                  Cytoplasm             8660
  ITGA6      Integrin, alpha 6                                                                             Plasma membrane       3655
  KCNH1      Potassium voltage-gated channel, subfamily H (eag-related), member 1                          Plasma membrane       3756
  KISS1      KiSS-1 metastasis-suppressor                                                                  Cytoplasm             3814
  LGALS3     Lectin, galactoside-binding, soluble, 3                                                       Extracellular space   3958
  LPA        Lipoprotein, Lp(a)                                                                            Extracellular space   4018
  LPHN2      Latrophilin 2                                                                                 Plasma membrane       23266
  LTA        Lymphotoxin alpha (TNF superfamily, member 1)                                                 Extracellular space   4049
  MAP2K5     Mitogen-activated protein kinase kinase 5                                                     Cytoplasm             5607
  MINK1      Misshapen-like kinase 1 (zebrafish)                                                           Cytoplasm             50488
  NOS3       Nitric oxide synthase 3 (endothelial cell)                                                    Cytoplasm             4846
  NOTCH4     Notch homolog 4 (Drosophila)                                                                  Plasma membrane       4855
  NRG1       Neuregulin 1                                                                                  Extracellular space   3084
  OAS3       2\'-5\'-oligoadenylate synthetase 3, 100 kDa                                                  Cytoplasm             4940
  P4HB       Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide   Cytoplasm             5034
  PKD1       Polycystic kidney disease 1 (autosomal dominant)                                              Plasma membrane       5310
  PLG        Plasminogen                                                                                   Extracellular space   5340
  PTPRF      Protein tyrosine phosphatase, receptor type, F                                                Plasma membrane       5792
  RASA1      RAS p21 protein activator (GTPase activating protein) 1                                       Cytoplasm             5921
  SERPINI2   Serpin peptidase inhibitor, clade I (pancpin), member 2                                       Extracellular space   5276
  SH3RF1     SH3 domain containing ring finger 1                                                           Cytoplasm             57630
  SOCS1      Suppressor of cytokine signaling 1                                                            Cytoplasm             8651
  TBC1D9     TBC1 domain family, member 9 (with GRAM domain)                                               Plasma membrane       23158
  TGFBR2     Transforming growth factor, beta receptor II (70/80 kDa)                                      Plasma membrane       7048
  TIAM1      T-cell lymphoma invasion and metastasis 1                                                     Cytoplasm             7074
  TNN        Tenascin N                                                                                    Plasma membrane       63923
  TPI1       Triosephosphate isomerase 1                                                                   Cytoplasm             7167
  VWF        von Willebrand factor                                                                         Extracellular space   7450
  WISP2      WNT1 inducible signaling pathway protein 2                                                    Extracellular space   8839
  WNT11      Wingless-type MMTV integration site family, member 11                                         Extracellular space   7481
  YWHAZ      Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide      Cytoplasm             7534

Biologically active estrogen and androgen metabolites
-----------------------------------------------------

In this study, we show that CAU-derived ECM enhanced the aggressiveness of ER^+^/PR^+^breast cancer cells, suggesting the microenvironment from which the ECM was derived may have been exposed to a different hormonal milieu compared to the AA. Therefore, the hormones present in the breast microenvironment were quantitatively measured by a novel method of LC-MS/MS that simultaneously extracted and analyzed biologically active estrogen and androgen metabolites present in whole tissue samples. Breast tissues from fasting, premenopausal AA and CAU women (median age 32 and 31, respectively; n = 19 AA and 20 CAU) were analyzed. Both androstenedione and testosterone were detected in all tissues (Figure [6a](#F6){ref-type="fig"}, Table [4](#T4){ref-type="table"}). Testosterone appeared elevated in the AA breast tissue; however, this observation was not statistically significant. It is of note that androgens levels were significantly higher in breast tissue compared to estrogens (*P*\< 0.001, Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}), similar to what has been repeatedly observed in blood. More importantly, these results shows that the unconjugated biologically active estrogens found in premenopausal breast tissues were higher than those reported in blood \[[@B39]\]. These results warrant further study given the role of estrogen metabolites in tumorigenesis.

###### 

Unconjugated biologically active androgens (pg/g) detected in breast tissue.

  Sample ID   Wet weight (g)   Androstenedione   Testosterone   Total
  ----------- ---------------- ----------------- -------------- ----------
  AA1         0.307            2,546.9           428.5          2,975.4
  AA2         0.293            2,393.9           422.5          2,816.4
  AA3         0.305            673.7             20,433.2       21,106.9
  AA4         0.290            2,922.5           628.7          3,551.2
  AA6         0.375            1,196.0           419.9          1,615.9
  AA7         0.317            6,634.4           872.9          7,507.3
  AA8         0.324            443.1             152.6          595.7
  AA10        0.272            2,748.0           470.5          3,218.6
  AA11        0.249            844.5             224.6          1,069.2
  AA12        0.270            1,099.8           184.6          1,284.4
  AA13        0.269            601.8             120.1          721.9
  AA14        0.289            2,890.2           373.8          3,264.0
  AA15        0.299            4,678.6           664.0          5,342.6
  AA16        0.345            832.0             184.3          1,016.3
  AA17        0.298            1,314.9           203.8          1,518.7
  AA18        0.299            562.4             667.5          1,229.9
  AA19        0.263            910.0             184.4          1,094.4
  AA5         0.348            1,588.9           227.4          1,816.3
  Mean        0.303            1,937.9           1,492.4        3,430.3
  SD          0.033            1,634.7           4,731.9        4,756.7
  SEM         0.008            385.3             1,115.3        1,121.2
  CA1         0.267            5,927.3           1,103.9        7,031.2
  CA2         0.283            1,904.7           178.2          2,082.9
  CA3         0.268            2,390.2           424.8          2,815.0
  CA4         0.328            311.5             141.4          452.9
  CA5         0.260            879.7             740.8          1,620.5
  CA6         0.294            962.5             211.5          1,173.9
  CA7         0.295            1,425.8           155.2          1,581.0
  CA8         0.260            515.2             180.6          695.8
  CA9         0.255            1,993.1           536.8          2,529.9
  CA10        0.324            710.3             588.4          1,298.7
  CA12        0.305            1,448.6           284.1          1,732.7
  CA14        0.208            1,540.4           361.3          1,901.8
  CA15        0.258            2,997.8           437.5          3,435.3
  CA16        0.319            1,068.2           4,855.9        5,924.1
  CA17        0.310            1,062.6           295.0          1,357.6
  CA18        0.297            3,515.1           343.6          3,858.7
  CA19        0.323            3,906.8           165.4          4,072.2
  CA20        0.312            3,070.7           95.9           3,166.6
  Mean        0.29             1,979.47          616.69         2,596.16
  SD          0.03             1,440.86          1,087.75       1,757.64
  SEM         0.01             339.61            256.38         414.28

SEM = standard error of the mean.

###### 

Unconjugated biologically active estrogens (pg/g) detected in breast tissue.

  Sample ID   Wet weight (g)   16KE2   E3       16aE1   16epiE3   17epiE3   3ME1   2ME1    4ME1   2ME2   E1       4ME2   E2       2OHE1   2OHE2   4OHE1   Total (pg/g)
  ----------- ---------------- ------- -------- ------- --------- --------- ------ ------- ------ ------ -------- ------ -------- ------- ------- ------- --------------
  AA1         0.307            ND      3.92     ND      ND        ND        ND     24.34   ND     ND     459.21   ND     138.15   ND      ND      ND      625.63
  AA2         0.293            ND      6.86     ND      ND        ND        ND     4.21    ND     ND     456.38   ND     210.90   ND      21.41   ND      699.77
  AA3         0.305            ND      6.44     ND      ND        ND        ND     4.33    ND     ND     26.35    ND     15.42    ND      ND      ND      52.55
  AA4         0.290            ND      7.33     ND      ND        ND        ND     4.23    ND     ND     314.41   ND     105.14   ND      14.77   ND      445.87
  AA5         0.348            ND      24.88    ND      ND        ND        ND     16.47   ND     ND     313.31   ND     69.34    ND      ND      ND      424.00
  AA6         0.375            ND      18.97    ND      ND        ND        ND     NF      ND     ND     106.18   ND     34.39    ND      ND      ND      159.54
  AA7         0.317            ND      43.72    ND      ND        ND        ND     5.49    ND     ND     728.23   ND     243.73   ND      ND      ND      1,021.17
  AA8         0.324            ND      4.38     ND      ND        ND        ND     14.50   ND     ND     248.02   ND     45.20    ND      ND      ND      312.10
  AA10        0.272            ND      11.02    ND      ND        ND        ND     NF      ND     ND     284.35   ND     103.53   ND      ND      ND      398.89
  AA11        0.249            ND      16.88    ND      ND        ND        ND     5.28    ND     ND     70.04    ND     44.63    ND      ND      ND      136.83
  AA12        0.270            ND      16.01    ND      ND        ND        ND     22.83   ND     ND     248.26   ND     38.55    ND      ND      ND      325.65
  AA13        0.269            ND      16.53    ND      ND        ND        ND     4.26    ND     ND     20.14    ND     4.47     ND      ND      ND      45.41
  AA14        0.289            ND      28.49    ND      ND        ND        ND     1.30    ND     ND     210.22   ND     59.68    ND      ND      ND      299.68
  AA15        0.299            ND      4.07     ND      ND        ND        ND     20.11   ND     ND     351.99   ND     141.77   ND      ND      ND      517.93
  AA16        0.345            ND      6.28     ND      ND        ND        ND     1.69    ND     ND     44.37    ND     19.59    ND      ND      ND      71.94
  AA17        0.298            ND      33.88    ND      ND        ND        ND     14.32   ND     ND     135.21   ND     17.07    ND      ND      ND      200.47
  AA18        0.299            ND      19.29    ND      ND        ND        ND     2.69    ND     ND     34.00    ND     1.21     ND      ND      ND      57.19
  AA19        0.263            ND      2.51     ND      ND        ND        ND     5.32    ND     ND     171.89   ND     36.87    ND      ND      ND      216.60
  Mean        0.30                     15.08                                       9.46                  234.59          73.87            18.09           333.96
  SD          0.03                     11.64                                       7.93                  187.28          70.29            4.69            261.24
  SEM         0.01                     2.74                                        1.87                  44.14           16.57            1.11            61.57
  CA1         0.267            ND      39.42    ND      ND        ND        ND     39.50   ND     ND     350.35   ND     120.01   ND      ND      ND      549.27
  CA2         0.283            ND      16.31    ND      ND        ND        ND     5.35    ND     ND     118.71   ND     385.77   ND      ND      ND      526.13
  CA3         0.268            ND      37.05    ND      ND        ND        ND     44.14   ND     ND     131.34   ND     146.55   ND      ND      ND      359.08
  CA4         0.328            ND      12.71    ND      ND        ND        ND     38.10   ND     ND     221.08   ND     615.33   ND      ND      ND      887.22
  CA5         0.260            ND      6.87     ND      ND        ND        ND     27.61   ND     ND     50.04    ND     100.53   ND      ND      ND      185.05
  CA6         0.294            ND      22.91    ND      ND        ND        ND     23.82   ND     ND     85.70    ND     36.74    ND      19.25   ND      188.41
  CA7         0.295            ND      49.19    ND      ND        ND        ND     NF      ND     ND     98.10    ND     32.98    ND      40.37   ND      220.63
  CA8         0.260            ND      23.83    ND      ND        ND        ND     10.86   ND     ND     34.00    ND     128.15   ND      ND      ND      196.85
  CA9         0.255            ND      26.86    ND      ND        ND        ND     54.25   ND     ND     266.36   ND     153.19   ND      ND      ND      500.66
  CA10        0.324            ND      15.30    ND      ND        ND        ND     10.95   ND     ND     61.18    ND     79.33    ND      ND      ND      166.76
  CA12        0.305            ND      45.37    ND      ND        ND        ND     16.33   ND     ND     158.05   ND     106.95   ND      ND      ND      326.70
  CA14        0.208            ND      67.15    ND      ND        ND        ND     25.67   ND     ND     337.20   ND     106.82   ND      ND      ND      536.84
  CA15        0.258            ND      25.99    ND      ND        ND        ND     31.21   ND     ND     167.88   ND     64.90    ND      ND      ND      289.98
  CA16        0.319            ND      32.34    ND      ND        ND        ND     26.20   ND     ND     351.61   ND     163.97   ND      ND      ND      574.12
  CA17        0.310            ND      17.61    ND      ND        ND        ND     5.73    ND     ND     135.22   ND     69.24    ND      ND      ND      227.80
  CA18        0.297            ND      101.07   ND      ND        ND        ND     63.23   ND     ND     174.84   ND     66.20    ND      ND      ND      405.34
  CA19        0.323            ND      9.35     ND      ND        ND        ND     17.33   ND     ND     63.77    ND     46.59    ND      ND      ND      137.03
  CA20        0.312            ND      19.01    ND      ND        ND        ND     26.06   ND     ND     78.28    ND     57.49    ND      ND      ND      180.83
  Mean        0.29                     31.57                                       27.43                 160.21          137.82           29.81           358.82
  SD          0.03                     23.25                                       16.40                 104.55          143.23           14.94           201.33
  SEM         0.01                     5.48                                        3.87                  24.64           33.76            3.52            47.45

ND = not detected; SEM = standard error of the mean.

![**Detection of estrogens and androgens in whole breast tissue**. Data represent the mean (n = 18 African-American (AA) and 20 Caucasian-American (CAU)) of biologically active androgens **(a)**or estrogens **(b)**± standard error analyzed via chromatography-tandem mass spectrometry. \**P*\< 0.005; Wilcoxon matched pairs or paired t test, accordingly.](1741-7015-8-27-6){#F6}

Of the 15 estrogen metabolites measured, only 5 were readily detectable as intrinsic components of breast tissue: estrone, estradiol, estriol, 2-methoxyestrone, and 2-hydroxyestradiol (Table [5](#T5){ref-type="table"}). Estradiol, estriol and 2-methoxyestrone were significantly higher in the CAU breast tissue (*P*\< 0.005), which was unanticipated given that previous studies have shown that premenopausal AA women have higher plasma concentrations of estrogens \[[@B40],[@B41]\]. Additionally, tissue levels of 2-hydroxyestradiol, a known carcinogen, were also detected in two patient samples, one from each group (Table [5](#T5){ref-type="table"}, mean pg/g = 18.1 ± 4.7 for AA and 29.8 ± 14.9 for CAU). The data presented here advocate for a more intensive analysis of the hormonal milieu of the breast microenvironment in addition to plasma levels, since local hormones are directly responsible for mediating cellular function and influence tumorigenesis.

Discussion
==========

This report is the first to analyze differences in the normal breast microenvironment of premenopausal women, and to show fundamental differences in the ability of breast ECM to influence the aggressiveness and tumorigenicity of breast cancer cells. The comprehensive LC-MS/MS identification of whole tissue hormone metabolites, as well as unique ECM proteins between the AA and CAU women, offers a novel insight into the intricacy of the breast microenvironment.

One limitation of this study, which must be addressed, is the lack of descriptive clinical data on the breast tissue isolated from the reduction mammoplasty patients. The tissue collected for fibroblast and whole breast tissue ECM isolation were considered pathological medical waste; therefore, informative clinical data including parity, body mass index, breast density, oral contraceptive use, phase of menstrual cycle were not available. Whether these important factors potentially had confounding effects on the observed results is regrettably unknown. In attempts to limit these effects, each experiment contained multiple replicates, and was repeated using as many different pools of patient samples feasible. A total of 50 CAU and 53 AA samples were used in the different analyses. However, the possibility remains that inherent factors from the tissue source could remain. Furthermore, we obtained samples from southern, eastern, and midwestern US, which may help eliminate the effects of socioeconomic factors if the samples had been obtained from one small geographical region. Determining whether clinical factors, or genetics, or a combination of the two, systematically relate as to why AAs develop a more aggressive cancer is not the purpose of this study. The objective of this study was not to determine how these discrepancies develop, but rather to use the information obtained to study their influence on breast cancer behavior. In addition, patient samples were pooled in order to obtain sufficient amount of ECM to perform these experiments. Although pooled samples are not ideal, a consistent pattern was observed with all results obtained even in this potentially confounding situation. Since no patient sample could be used twice, this suggests that our conclusions were not skewed by any single sample. Future studies to determine specific components in ECM responsible for these effects will require examination of individual tissues, if enough material becomes available from a single patient. Overall, the results presented provide valuable data for further investigation into the role of the microenvironment in cancer disparities, and potentially as a basis for future studies investigating factors such as parity and phase of menstrual cycle on breast cancer cell behavior.

Collectively, the data presented in this report suggest that the AA breast microenvironment is less permissive of tumor growth compared to the CAU breast microenvironment. Therefore, it is not surprising that only the more aggressive cells are able to survive and proliferate unrestrictedly in the suppressive microenvironment of AA breast tissue. The comparatively suppressive effects of the AA ECM may arise from both a physical restriction due to the types of structural material present in the ECM, and chemically from the signals present, or absent, in the microenvironment. Numerous reports have indicated that the spatial organization and composition of the ECM influence mammary cell behavior, and that alterations in ECM receptor expression facilitate malignant transformation \[[@B42]\].

The premenopausal stroma is not a static compartment; proliferation in the breast varies with the menstrual cycle, which requires the expansion and deposition of new ECM \[[@B43]\]. Increased deposition of molecules such as collagen can alter the ECM biophysical properties and increase extracellular cellular tension. ECM composition and rigidity modulate cell-ECM interactions and have a significant impact on cell functions. Indeed, mammary epithelial cells cultured on matrices with increased stiffness have disrupted cell-cell junctions, increased proliferation, perturbed endogenous basement membrane assembly, and a dedifferentiated phenotype \[[@B44],[@B45]\]. The development of breast cancer is characterized by the loss of tissue organization and an increase in tissue rigidity, suggesting that aberrant tension may facilitate the acquisition of a malignant phenotype \[[@B45]\]. For example, primary mammary epithelial cells cultured on floating collagen gels were shown to differentiate in response to lactogenic hormones only when plated on collagen gels with reduced tensional forces. When plated on gels with increased tension, the extracellular forces promoted cell spreading, increased MMP activity, and inhibited acini formation and cellular differentiation \[[@B46]\]. Interestingly, triple-negative tumors (ER^-^/PR^-^and lacking HER2 amplification) are composed of undifferentiated cells, potentially resulting from a small, localized area of matrix stiffness and high tension. Paszek *et al.*demonstrated that matrix stiffness promotes tumor-like behavior in mammary cells, and blocking integrin-dependent cell contractility reverted the malignant phenotype in culture \[[@B44]\]. Thus, if the premenopausal AA microenvironment is comparatively more restrictive in its composition/organization, as our data suggests, this may predispose AAs to triple-negative breast cancer. Further studies on this topic are warranted.

The use of a selective pressure to isolate a more tumorigenic cell is often used in studies seeking to identify the progenitor tumor-initiating cells (cancer stem cell) via culturing the cells in non-adherent conditions \[[@B47]\]. The rationale driving this culture system is that only the progenitor tumor-initiating cells are able to survive and self-renew when contact with the ECM is disrupted, whereas differentiated, non-tumor initiating cells experience anoikis and die \[[@B48]\]. Potentially a similar mechanism of selective pressure is actively selecting for the more aggressive cancer cell in the restrictive premenopausal AA microenvironment.

It is noteworthy that the invasiveness, tumorigenicity, and metastases of the ER^+^/PR^+^cells were enhanced in the presence of the CAU ECM. It has been similarly shown that breast cancer cell proliferation, in response to androgens, was dependent upon both the ER status of the cell and signals from the ECM. Specifically, ER^+^MCF7 cells proliferated in the presence of dihydrotestosterone (DHT) by an ERα-dependent mechanism; however, MDA-MB-231 cells responded to DHT by an ER-independent, αvβ3 integrin pathway \[[@B49]\]. Additional estrogen and ECM/integrin interactions related to tumorigenesis have been reported. Hypoxia-inducible factor 1α (HIF-1α), a transcription factor which is overexpressed in the majority of human carcinomas and controls central metastasis-associated pathways, was shown to increase anchorage-independent growth by downregulation of the α5 integrin \[[@B50]\]. Anchorage independent growth and decreased α5 integrin levels were reverted by treatment with the estrogen metabolite, 2-methoxyestradiol, a known pharmacological inhibitor of HIF-1α.

This is the first report to simultaneously analyze the biologically-active estrogens and androgens from each patient in whole breast tissue via LC-MS/MS; previous studies measured blood and urine levels. This method offers a more intimate analysis of the local hormone milieu of the breast microenvironment, compared to measuring circulating levels of hormones. Indeed, it is now well known that the local synthesis from the stromal cells dramatically contributes to the growth, function, and tumorigenesis of ER/PR positive and negative breast cells \[[@B51]-[@B53]\]. BRCA1 tumors, the majority of which are ER^-^, have been effectively prevented by ovariectomy \[[@B54]\]. Furthermore, it is proposed that the increased risk of breast cancer following pregnancy is due to high levels of estrogen and other pregnancy associated hormones that promote the growth of already initiated target cell populations \[[@B55]\]. Interestingly, the majority of breast cancers that develop during this time are ER^-^/PR^-^suggesting that hormones affect the local microenvironment.

Different estrogen metabolites have been reported to act as either carcinogens or to protect from tumorigenesis, although their precise mechanisms are yet to be fully defined. The production of 16α-hydroxyestrone has been hypothesized to initiate breast cell transformation by acting as an estrogen agonist, increasing cellular proliferation and generating reactive oxygen species thereby causing DNA damage \[[@B56]\]. Conversely, 2-hydroxyestradiol has been shown to possess estrogen antagonist properties *in vivo*\[[@B56]\]. In this report, the primary estradiol/estrone metabolites detected were estriol, a product of the 16α-hydroxylation pathway, and 2-methoxyestrone, a product of the 2-hydroxylation pathway. It is of note that these two metabolites appear to be equally balanced in the tissue, as it has been shown that alterations in the ratio of C2/C16 estradiol/estrone hydroxylation can lead to anchorage-independent growth and tumorigenesis \[[@B57]\]. Analysis of these hormone metabolites in breast tissue, as opposed to circulating levels, could potentially be used for early detection of breast cancer in high-risk patients.

Our understanding of the interactions between the numerous cell types within breast, especially during tumorigenesis, still remains vague owing to the complexity of physical and chemical communication, and inherent differences between patients and their resultant types of cancer. However, apart from individual patient differences, there is indisputable evidence that breast carcinomas in premenopausal AA women tend to be triple negative and highly metastatic compared to breast carcinomas in CAU women. Identifying the initiating factors in the development of triple-negative breast cancer in premenopausal AA women will fill a gap of knowledge in breast cancer research. Why these women should have an increased incidence of this disease compared to other racial groups remains elusive.

Conclusions
===========

This report details the importance of the normal breast microenvironment on breast cancer cell behavior, an essential step in the investigation of the etiology of breast cancer. The data presented characterize the composition of normal premenopausal breast tissue and provides data for further investigation into the role of the microenvironment in cancer disparities.
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**Supplementary table and figures**. Table S1: Real-time PCR primer sequences. Figure S1. Tumor characterization. **(a,b)**Humanized murine mammary glands, injected with primary metastatic breast cancer cells were stained for Ki67 **(a)**. Bar = 200 μm. Percentage proliferation: number of positive per total live cells in a minimum of three fields. **(b)**Representative hematoxylin and eosin (H&E)-stained section. Bar = 2,000 μm. Overt necrosis was determined using AxioVision Imaging software version 4.8. Data represent mean ± standard error. AA = African-American, CAU = Caucasian-American. Figure S2. Validation of qPCR arrays. Breast fibroblasts pools, derived from a minimum of three age-matched patients, were analyzed per array. Graphs represent fold increase of differentially regulated genes. Figure S3. Soft agar growth assay. Cell lines were assayed and stained with nitrobluetetrazolium before counting. Representative images of a minimum of two experiments per cell line. Bar = 200 μm. Figure S4. Representative MS/MS spectra of peptides identified from breast tissue ECM proteins. A = hornerin; B = wnt10a; C = vimentin; D = cytokeratin 19. Figure S5. *In silico*analysis in African-American extracellular matrix protein molecules. **(a-d)**Top signaling network of unique proteins. Mapped identifiers (shown in gray) were overlaid onto a global molecular network developed from information contained in the Ingenuity knowledge base. Networks were then algorithmically generated based on their connectivity and incorporated with other molecules with high connectivity (white). Nodes associated with breast cancer according to the IPA knowledge base, are utlined in yellow. Figure S6. *In silico*analysis in Caucasian-American extracellular matrix protein molecules. **(a-d)**As for Figure S5.
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